468 related articles for article (PubMed ID: 28575273)
1. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.
Danese S; Bonovas S; Peyrin-Biroulet L
J Crohns Colitis; 2017 Oct; 11(10):1258-1266. PubMed ID: 28575273
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab (Stelara) for Crohn's disease.
Med Lett Drugs Ther; 2017 Jan; 59(1511):5-6. PubMed ID: 28026835
[No Abstract] [Full Text] [Related]
3. Ustekinumab: A Review in Moderate to Severe Crohn's Disease.
Lamb YN; Duggan ST
Drugs; 2017 Jul; 77(10):1105-1114. PubMed ID: 28528528
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab: a novel therapeutic option in Crohn's disease.
Simon EG; Samuel S; Ghosh S; Moran GW
Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P; Sandborn WJ
Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
[TBL] [Abstract][Full Text] [Related]
6. Update on ustekinumab for the treatment of Crohn's disease.
Leung Y; Panaccione R
Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P; Loftus EV
Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.
Kawalec P; Moćko P; Malinowska-Lipien I; Brzostek T
J Comp Eff Res; 2017 Oct; 6(7):601-612. PubMed ID: 28660802
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Grimaud JC; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):242-50.e1-2. PubMed ID: 26432476
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.
D'Amico F; Peyrin-Biroulet L; Danese S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii30-ii41. PubMed ID: 35553665
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab for the treatment of Crohn's disease.
Hansen T; Targownik LE
Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.
Aggeletopoulou I; Assimakopoulos SF; Konstantakis C; Triantos C
World J Gastroenterol; 2018 Sep; 24(36):4093-4103. PubMed ID: 30271076
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P;
Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab to treat Crohn's disease.
Gisbert JP; Chaparro M
Gastroenterol Hepatol; 2017 Dec; 40(10):688-698. PubMed ID: 29042094
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab: moving the target from psoriasis to Crohn's disease.
Settesoldi A; Coppola M; Rogai F; Annese V
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):5-13. PubMed ID: 24410468
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
17. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
Macaluso FS; Orlando A; Cottone M
Expert Opin Biol Ther; 2019 Feb; 19(2):89-98. PubMed ID: 30571147
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
Casas Deza D; García López S; Lafuente Blasco M; Vicente Lidón R; Nerín de la Puerta J; Peña Gonzalez E; Ber Nieto Y; Charro Calvillo M; Alcalá Escriche MJ; Gomollón García F; Arroyo Villarino M
Gastroenterol Hepatol; 2020 Mar; 43(3):126-132. PubMed ID: 31866167
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
